Human Polyclonal GDF15 Ab
- Known as:
- Human Polyclonal GDF15 Antibody
- Catalog number:
- a0185
- Product Quantity:
- USD
- Category:
- -
- Supplier:
- ABclonal
- Gene target:
- Human Polyclonal GDF15
Related genes to: Human Polyclonal GDF15 Ab
- Gene:
- GDF15 NIH gene
- Name:
- growth differentiation factor 15
- Previous symbol:
- -
- Synonyms:
- PLAB, MIC-1, PDF, MIC1, NAG-1, PTGFB
- Chromosome:
- 19p13.11
- Locus Type:
- gene with protein product
- Date approved:
- 2004-02-12
- Date modifiied:
- 2018-01-16
Related products to: Human Polyclonal GDF15 Ab
Related articles to: Human Polyclonal GDF15 Ab
- Insulin resistance (IR) correlates with a wide spectrum of diseases and death. However, the specific proteomic signatures of IR and their associations with health outcomes remain incompletely understood. - Source: PubMed
Publication date: 2026/07/12
Zhou Zong-LeiZhou Li-GangQu Chun-HuaFan Chun-XiangQu Hai-HongLi JunWei Cheng-XiaWang WuBao Xu-HuiLi Ji-Yu - Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy with a rising global incidence. Differentiating PDAC from non-malignant pancreatic conditions, particularly chronic pancreatitis (CP), remains challenging due to overlapping clinical and radiological features, highlighting the need for new biomarkers. The best-validated serum biomarker, carbohydrate antigen 19-9 (CA19-9), has limited clinical utility due to its suboptimal sensitivity and specificity. This study aimed to evaluate the diagnostic performance of serum macrophage inhibitory cytokine 1 (GDF15), syncollin (SYCN), and thrombospondin-2 (TSP-2), both alone and in multi-marker panels, for differentiating PDAC from CP and healthy controls (HCs). The selection of these markers was based on prior evidence linking GDF15 to PDAC diagnosis and prognosis, SYCN to pancreatic tissue damage, and TSP-2 to tumor microenvironment remodeling. - Source: PubMed
Publication date: 2026/06/26
Wieczorek MichalinaWieczorek LukaszBorkowska AnnaMalecka-Wojciesko Ewa - Resistance to anti-PD-1/PD-L1 therapy is a major unmet need. Growth Differentiation Factor 15 (GDF-15) has been identified as a key resistance factor for anti-PD-1/PD-L1 immunotherapy. Visugromab, a neutralizing anti-GDF-15 antibody, plus the anti-PD-1 antibody nivolumab (V+N) was evaluated in the first-in-human phase 1/2a GDFATHER-01 trial in heavily pretreated participants with locally advanced/metastatic non-squamous non-small-cell lung cancer (nsq NSCLC), urothelial carcinoma (UC), or hepatocellular carcinoma (HCC), stringently defined as anti-PD-1/PD-L1-relapsed/refractory, and showed encouraging objective responses. This analysis reports long-term follow-up of these three phase 2 expansion cohorts of the GDFATHER-01 trial. - Source: PubMed
Publication date: 2026/07/09
Melero Ignaciode Miguel MaríaCabanas Elena Garraldade Velasco GuillermoJoerger MarkusMartín-Liberal JuanReig MariaKönig DavidTrojan JoergGoebeler Maria-ElisabethSchuler MartinAlonso GuzmanDummer ReinhardRodríguez-Ruiz Maria EYarza RamónPretelli GiuliaEsteban-Villarubia JorgeKoster Kira-LeeViltro Paula SabatSanduzzi-Zamparelli MarcoLäubli HeinzKoch ChristineSayehli CyrusGromke TanjaRacca FabricioRamelyte EgleGalle Peter RNecchi AndreaReck MartinTrajanoski ZlatkoHackl HubertGogolla FalkBilling JaclynSattmann TeresaWischhusen JörgSchuberth-Wagner ChristineAkdemir JuliaLichtenegger Felix SAuckenthaler AlexandraFox MarleneKlar KathrinFettes PetraLiebig MaraAmin AasimSachdeva SheenaHermann FrankLeo Eugen - Acute toxoplasmosis could be life-threatening, as the body is overwhelmed both by the rapidly replicating tachyzoites and the immunopathological sequelae of the robust immune response with no satisfactory treatment or vaccine available to date. Fluoxetine, a selective serotonin reuptake inhibitor, is recently repurposed to control cytokine storm in certain clinical settings. In this study, an animal model of acute toxoplasmosis was established using the virulent RH strain. To compare their therapeutic effects, either spiramycin or fluoxetine was administered for 5 days starting from the day of infection. To assess its prophylactic effects, fluoxetine was started 2 weeks before induction of the infection. It was found that fluoxetine as well as spiramycin achieved comparable reduction of the tachyzoite counts with prominent deleterious morphological effects on the tachyzoites detected by scanning electron microscopy. Both drugs improved the histopathological changes with superior effect of fluoxetine, particularly in the brain. Fluoxetine attenuated substantially the inflammatory response through the reduction of TNF-α, IL-4 and MCP-1 levels. Prophylactic fluoxetine administration also induced improvement of the redox status. Moreover, fluoxetine exhibited superior effect in reversal of infection-induced modulation of apoptosis and vascular dysfunction in the brain via significantly reducing the levels of p21 and endocan, respectively. Fluoxetine also upregulated the levels of growth differentiation factor 15 in the spleen, partly accounting for the limitation of the immunopathology. In conclusion, fluoxetine showed antiparasitic activity comparable to that of spiramycin, and displayed superior anti-inflammatory, immunomodulatory, vascular protective and pro-apoptotic effects, leading to better survival in acute murine toxoplasmosis. - Source: PubMed
Elgendy Wesam M AOthman Ahmad AKhalifa Basma NSoliman Nema AMohamed DareenYounis Salwa S - Growth differentiation factor (GDF)-15 is associated with various conditions such as cardiovascular disease, inflammation, and chronic kidney disease. Phase angle (PhA) reflects cellular health and nutritional status. However, the relationship between serum GDF-15 concentrations and PhA is unclear. - Source: PubMed
Publication date: 2026/07/08
Fukuda TairaKondo KanNishikawa RiichiHirai RinaIshizaka HayatoTan HideakiNozawa NaohiroTokoi SeikoHirose SuguruYamaguchi SuomiYagi HiroshiArikawa TakuoAmano HirohisaSakuma MasashiShibasaki IkukoFukuda HirotsuguToyoda ShigeruNakajima Toshiaki